Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 482

1.

International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.

Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR.

Curr Med Res Opin. 2014 Dec;30(12):2437-42. doi: 10.1185/03007995.2014.957822. Epub 2014 Sep 2.

PMID:
25170587
2.

Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.

Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsattar Y, Chakrabarti A, Wang J.

J Manag Care Spec Pharm. 2015 Jul;21(7):596-606.

3.

International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.

Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR.

Am J Cardiovasc Drugs. 2015 Jun;15(3):205-11. doi: 10.1007/s40256-015-0120-9.

4.

Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation.

Nelson WW, Milentijevic D, Wang L, Baser O, Damaraju CV, Schein JR.

Blood Coagul Fibrinolysis. 2016 Dec;27(8):899-906.

PMID:
26886362
5.

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE.

N Engl J Med. 2003 Sep 11;349(11):1019-26.

6.

Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.

Baker WL, Cios DA, Sander SD, Coleman CI.

J Manag Care Pharm. 2009 Apr;15(3):244-52.

7.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
8.
9.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

10.

Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.

Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L.

Chest. 2004 Dec;126(6):1938-45. Review.

PMID:
15596696
11.

Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry.

Wang C, Yang Z, Wang C, Wang Y, Zhao X, Liu L, Wang DZ, Li H, Wang Y.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1157-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.006. Epub 2013 Dec 2.

PMID:
24291013
13.

Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.

Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators..

Am Heart J. 2015 Jul;170(1):141-8, 148.e1. doi: 10.1016/j.ahj.2015.03.017. Epub 2015 Apr 1.

14.

Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]).

Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R, Goldbourt U, Tsabari R, Koton S, Grossman E, Tanne D.

Am J Cardiol. 2010 Feb 1;105(3):411-6. doi: 10.1016/j.amjcard.2009.09.050. Epub 2009 Dec 22.

PMID:
20102959
15.

National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation.

Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, Hylek EM.

Circulation. 2014 Apr 1;129(13):1407-14. doi: 10.1161/CIRCULATIONAHA.113.002601. Epub 2014 Feb 3.

16.

Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.

Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR.

J Med Econ. 2015 May;18(5):333-40. doi: 10.3111/13696998.2014.1001851. Epub 2015 Feb 6.

PMID:
25549062
17.

Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims.

Qualls LG, Greiner MA, Eapen ZJ, Fonarow GC, Mills RM, Klaskala W, Hernandez AF, Curtis LH.

Clin Cardiol. 2013 Dec;36(12):757-65. doi: 10.1002/clc.22206. Epub 2013 Oct 1.

18.
20.

Supplemental Content

Support Center